Provided by Tiger Trade Technology Pte. Ltd.

bioAffinity Technologies, Inc.

5.19
-0.6300-10.82%
Post-market: 5.250.0600+1.16%17:27 EDT
Volume:87.83K
Turnover:467.71K
Market Cap:3.07M
PE:-0.05
High:5.47
Open:5.40
Low:5.08
Close:5.82
52wk High:202.50
52wk Low:4.88
Shares:592.37K
Float Shares:532.20K
Volume Ratio:0.04
T/O Rate:16.50%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-103.3545
EPS(LYR):-129.9452
ROE:-1860.15%
ROA:-125.11%
PB:0.82
PE(LYR):-0.04

Loading ...

NASDAQ Trade Halt Continues Reason not Available at 03:58 Am

Reuters
·
Aug 24

bioAffinity Technologies Inc trading halted, news pending

TIPRANKS
·
Aug 22

bioAffinity Technologies Effects 1-for-15 Reverse Stock Split Effective Aug. 24, 2026

Reuters
·
Aug 20

bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026

THOMSON REUTERS
·
Aug 20

bioAffinity Signs AvMEDICAL Distribution Deal for CyPath Lung in Federal Healthcare Market

Reuters
·
Aug 18

bioAffinity Technologies and Avmedical Announce Nationwide Federal Healthcare Distribution Agreement for Cypath® Lung

THOMSON REUTERS
·
Aug 18

BioAffinity Technologies announces closing of $4M private placement offering

TIPRANKS
·
Aug 16

bioAffinity Technologies Closes $4 Million Private Placement of Pre-Funded Warrants Priced at $0.47

Reuters
·
Aug 14

bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under NASDAQ Rules

THOMSON REUTERS
·
Aug 14

bioAffinity Technologies Prices USD 4 Million Private Placement at USD 0.47 Per Share Unit

Reuters
·
Aug 13

bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under NASDAQ Rules

THOMSON REUTERS
·
Aug 13

Heron Therapeutics Q2 Revenue Rises on Acute Care Growth, Withdraws 2026 Outlook

Reuters
·
Aug 10

bioAffinity Technologies Q2 Net Income USD -3.4 Million

THOMSON REUTERS
·
Aug 07

bioAffinity Technologies Q2 EPS $(0.64) Beats $(2.40) Estimate, Sales $1.511M Beat $1.483M Estimate

Benzinga Earnings
·
Aug 07

bioAffinity Q2 FY26 Net Loss Narrows to $3.4 Million; Revenue Rises 19% to $1.5 Million

Reuters
·
Aug 07

Press Release: bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath(R) Lung

Dow Jones
·
Aug 07

bioAffinity Technologies Faces NASDAQ Delisting Risk After Shares Trade Below $1 Bid-price Minimum

Reuters
·
Aug 01

BioAffinity announces publication of clinical review on CyPath Lung

TIPRANKS
·
Jul 27

bioAffinity Publishes Clinical Framework Targeting Pulmonary Nodule Risk Stratification Market

Reuters
·
Jul 27

Bioaffinity Technologies - Tests Expected to be Offered as Laboratory Developed Tests Under Clia

THOMSON REUTERS
·
Jul 22